Immunic Exercises its Worldwide Exclusive Option to License for IMU-856 with Daiichi Sankyo

Daiichi Sankyo’s Turalio (pexidartinib) Receives the US FDA’s Approval for the Symptomatic Tenosynovial Giant Cell Tumor


  • Immunic has exercised its exclusive option to license a group of compounds for Daiichi’s IMU-856. Daiichi to receive up front, certain future development, approval & sales milestone payments plus royalties on IMU-856. Immunic to get exclusive commercialization rights for IMU-856 in all countries, including the US, EU, and Japan
  • Additionally, the option includes patent exclusivity filled by Daiichi for IMU-856’s composition of matter. In Nov, 2018 Daiichi signed an exclusive WW option and license agreement with Immunic for IMU-856
  • IMU-856 is an orally administered modulator that restores the intestinal barrier function developed originally by Daiichi and will be evaluated in P-I for patients suffering from gastrointestinal diseases in H1’20

Click here to read full press release/ article | Ref: Immunic | Image: Behance